EXTON, Pa., Sept. 7 /PRNewswire-FirstCall/ -- Fibrocell Science, Inc. (OTC Bulletin Board: FCSC), a biotechnology company focused on the development of autologous cell therapies for aesthetic, medical and scientific applications, announced today the appointment of Stefan Gruenwald, M.D., Ph.D., to its scientific advisory board. In addition to being a renowned molecular and cellular biologist, Dr. Gruenwald is a biotechnology and genetic research expert. Dr. Gruenwald also has vast experience in management of biotechnology, start-up and Fortune 100 companies; mergers and acquisitions; venture capital and private equity; international business; and nanotechnology investment.
"We are fortunate at Fibrocell Science to have assembled a well-rounded, impressive group of scientific advisors in the last several months," said David Pernock, Chairman and CEO. "As our newest addition, Dr. Gruenwald's scientific expertise and business acumen adds unique value as we consider broad uses for our technology platform. Our collaboration with Dr. Gruenwald will enable us to explore multiple new scientific pathways with the potential for near-term implementation."
About Dr. Gruenwald
Dr. Gruenwald's career in life sciences spans more than two decades. He earned both his medical and doctoral degrees at the Johann-Wolfgang Goethe University in Frankfurt, Germany, receiving the Friends of Paul Ehrlich Award for the best thesis of the year summa cum laude. He later completed post-doctoral research at the Scripps Research Institute and the University of California San Diego.
In 1991, Dr. Gruenwald joined the newly formed PharMingen (now a part of BD Biosciences), which became one of the most successful San Diego-based biotechnology companies. As Vice President of Research & Development at PharMing
|SOURCE Fibrocell Science, Inc.|
Copyright©2010 PR Newswire.
All rights reserved